Literature DB >> 14523647

The role of bisphosphonates in diseases of childhood.

Tarak Srivastava1, Uri S Alon.   

Abstract

Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption by their action on osteoclasts. In recent years, bisphosphonates have been used in children for treatment of a growing number of disorders associated primarily with generalized or localized osteoporosis, metabolic bone diseases, heterotopic calcification in soft tissues, and for resistant hypercalcemia. In the present review we discuss the pharmacological aspects of bisphosphonates and related bone pathophysiology, review the pediatric literature on the role of bisphosphonates in childhood diseases and our experience with these drugs. The theoretical concerns of possible adverse effects of these drugs on the growing skeleton have not materialized in the limited pediatric clinical experience. Bisphosphonates provide the pediatrician with an opportunity to treat mineral and bone disorders of childhood which until recently did not have satisfactory therapy, at the same time, being aware of the theoretical concerns on microdamage accumulation in bone, bone quality and teratogenic potential of these drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523647     DOI: 10.1007/s00431-003-1298-4

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  123 in total

1.  Bisphosphonates: oesophageal and gastric toxicity--fact or fiction.

Authors:  F L Lanza
Journal:  Ital J Gastroenterol Hepatol       Date:  1998-04

2.  Is APD a promising drug in the treatment of severe osteogenesis imperfecta?

Authors:  J P Huaux; W Lokietek
Journal:  J Pediatr Orthop       Date:  1988 Jan-Feb       Impact factor: 2.324

Review 3.  Bisphosphonates: from grandparents to grandchildren.

Authors:  T Srivastava; U S Alon
Journal:  Clin Pediatr (Phila)       Date:  1999-12       Impact factor: 1.168

4.  The osteodystrophy of congenital erythropoietic porphyria.

Authors:  H W Pullon; A J Bellingham; S Humphreys; T F Cundy
Journal:  Bone       Date:  1991       Impact factor: 4.398

5.  Intravenous pamidronate treatment in osteogenesis imperfecta.

Authors:  B Bembi; A Parma; M Bottega; S Ceschel; M Zanatta; C Martini; G Ciana
Journal:  J Pediatr       Date:  1997-10       Impact factor: 4.406

6.  Idiopathic infantile arterial calcification: unusual features.

Authors:  J Vera; J Lucaya; J A Garcia Conesa; C Aso; A Balaguer
Journal:  Pediatr Radiol       Date:  1990

Review 7.  Osteogenesis imperfecta: practical treatment guidelines.

Authors:  F Antoniazzi; M Mottes; P Fraschini; P C Brunelli; L Tatò
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

8.  Pharmacokinetics of clodronate in renal failure.

Authors:  H Saha; P Castren-Kortekangas; S Ojanen; A Juhakoski; J Tuominen; O Tokola; A Pasternack
Journal:  J Bone Miner Res       Date:  1994-12       Impact factor: 6.741

Review 9.  Impact of lung inflammation on bone metabolism in adolescents with cystic fibrosis.

Authors:  S P Conway
Journal:  Paediatr Respir Rev       Date:  2001-12       Impact factor: 2.726

10.  Bisphosphonates in the treatment of thalassemia-induced osteoporosis.

Authors:  N Morabito; A Lasco; A Gaudio; A Crisafulli; C Di Pietro; A Meo; N Frisina
Journal:  Osteoporos Int       Date:  2002-08       Impact factor: 4.507

View more
  16 in total

Review 1.  Vitamin D intoxication and therapy with alendronate (case report and review of literature).

Authors:  Zerrin Orbak; Hakan Doneray; Filiz Keskin; Ahmet Turgut; Handan Alp; Cahit Karakelleoglu
Journal:  Eur J Pediatr       Date:  2006-04-29       Impact factor: 3.183

2.  Idiopathic infantile arterial calcification: clinical presentation, therapy and long-term follow-up.

Authors:  Inge M van der Sluis; Annemieke M Boot; Meike Vernooij; Morteza Meradji; André A Kroon
Journal:  Eur J Pediatr       Date:  2006-04-29       Impact factor: 3.183

Review 3.  Osteoporosis in juvenile idiopathic arthritis--a practical approach to diagnosis and therapy.

Authors:  Johannes Roth; Susanne Bechtold; Gudrun Borte; Frank Dressler; Hermann J Girschick; Michael Borte
Journal:  Eur J Pediatr       Date:  2007-04-14       Impact factor: 3.183

4.  Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report.

Authors:  Ana Luiza Andrade Aragão; Ivani Novato Silva
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-21

5.  Pamidronate distribution in pediatric renal and rheumatologic patients.

Authors:  Philip D Acott; Jaime A Wong; John F S Crocker; Bianca Lang; Patrick O'Regan; Kenneth W Renton
Journal:  Eur J Clin Pharmacol       Date:  2006-10-06       Impact factor: 2.953

6.  Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children.

Authors:  Kim M Waterhouse; Ari Auron; Tarak Srivastava; Connie Haney; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2006-10-11       Impact factor: 3.714

7.  Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy.

Authors:  Simon Waller; Tom Kurzawinski; Lewis Spitz; Rajesh Thakker; Treena Cranston; Simon Pearce; Tim Cheetham; William G van't Hoff
Journal:  Eur J Pediatr       Date:  2004-10       Impact factor: 3.183

8.  Effect of alendronate on the mandible and long bones: an experimental study in vivo.

Authors:  Sharon R Oyhanart; Natalia D Escudero; Patricia M Mandalunis
Journal:  Pediatr Res       Date:  2015-09-02       Impact factor: 3.756

9.  Alendronate treatment promotes bone formation with a less anisotropic microstructure during intramembranous ossification in rats.

Authors:  Masafumi Kashii; Jun Hashimoto; Takayoshi Nakano; Yukichi Umakoshi; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

10.  Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases.

Authors:  Yuzaburo Inoue; Naoki Shimojo; Shuichi Suzuki; Takayasu Arima; Minako Tomiita; Masanori Minagawa; Yoichi Kohno
Journal:  Clin Rheumatol       Date:  2008-03-11       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.